ASIT Biotech - Setting the stage for the confirmatory Phase III
ASIT Biotech’s H1 results statement included an outline of its preparations for the confirmatory Phase III study of its short-course gp-ASIT+ for grass pollen allergy, including the appointment of a single CRO. ASIT’s H118 operating loss was €5.4m, within which R&D comprised €4.5m. End of June net cash of €13.0m and the July convertible bond issue leave ASIT comfortably funded through 2020 in our model.Asit Biotech SA. Asit Biotech SA, formerly Biotech Tools SA, is a Belgium- based company that develops products aimed to prevent negative response of the immune system.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.